New Product Watch | GenomeWeb

New Product Watch


Mobidiag last week said that it has CE marked its Prove-it Herpes virus microarray for in vitro detection of central nervous system infections. The Helsinki, Finland-based firm said the CE mark ensures the safety of the product in clinical use and opens European markets for its test. Prove-it Herpes identifies seven herpesviruses in a single assay. Prove-it Herpes was developed in co-operation with the Hospital Districts of Helsinki and Uusimaa and the University of Helsinki, Mobidiag said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.